|
Orthologous residues
|
|
TrkA (human): Y791‑p, TrkA iso2 (human): Y785‑p, TrkA (mouse): Y794‑p, TrkA (rat): Y794‑p, TrkA iso2 (rat): Y788‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, western blotting
|
|
Disease tissue studied:
adrenal cancer, pheochromocytoma
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), PC-12 (chromaffin)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
augment treatment-induced increase
|
|
|
vanadate
|
|
|
|
increase
|
|
|
NGF
|
vanadate
|
|
|
augment treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
PLCG1 (human)
|
|
Induces
|
phosphorylation
|
|
sequence-specific competitor, in vitro, co-immunoprecipitation
|
|
|
Comments:
association in vitro and in vivo
|
